Research graph
References from Pharmaco-multiomics in major depressive disorder: a narrative review and proposed translational framework for difficult-to-treat and treatment-resistant depression. Local targets link to admitted publications; unresolved targets remain external evidence.
Understanding treatment-resistant depression using omics techniques: a systematic review
10.1016/j.jad.2022.09.011 · 2022 · External reference
Machine learning for antidepressant treatment selection in depression
10.1016/j.drudis.2024.104068 · 2024 · External reference
Pharmacogenomic testing in depression: a systematic review and meta-analysis of randomized controlled trials
10.1016/j.neubiorev.2022.104966 · 2023 · External reference
Pharmacogenomics-driven prediction of antidepressant treatment outcomes: a machine-learning approach with multi-trial replication
10.1002/cpt.1482 · 2019 · External reference
Dutch Pharmacogenetics Working Group guideline for the gene-drug interaction between CYP2D6, CYP2C19 and non-SSRI/non-TCA antidepressants
10.1038/s41431-024-01648-1 · 2024 · External reference
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants
10.1002/cpt.2903 · 2023 · External reference
Dutch Pharmacogenetics Working Group guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs
10.1038/s41431-021-01004-7 · 2022 · External reference
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis: the TRIPOD statement
10.7326/m14-0697 · 2015 · External reference
Metabolomics of major depressive disorder: a systematic review of clinical studies
10.7759/cureus.23009 · 2022 · External reference
Leveraging DNA methylation to predict treatment response in major depressive disorder: a critical review
10.1002/ajmg.b.32985 · 2024 · External reference
Pharmaco-multiomics: a new frontier in precision psychiatry
10.3390/ijms26031082 · 2025 · External reference
Medication use is associated with distinct microbial features in anxiety and depression
10.1038/s41380-024-02857-2 · 2025 · External reference
Prevalence of CYP2D6 structural variation in large retrospective study
10.1097/fpc.0000000000000525 · 2024 · External reference
Multi-omic modeling of antidepressant response implicates dynamic immune and inflammatory changes in individuals who respond to treatment
10.1371/journal.pone.0285123 · 2023 · External reference
Inflammatory biomarker and response to antidepressant in major depressive disorder: a systematic review and meta-analysis
10.64719/pb.4425 · 2022 · External reference
Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder
10.3389/fphar.2022.984383 · 2022 · External reference
Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial
10.1016/j.jpsychires.2019.01.003 · 2019 · External reference
Effect of minocycline on depressive symptoms in patients with treatment-resistant depression: a randomized clinical trial
10.1001/jamanetworkopen.2022.30367 · 2022 · External reference
Machine learning for comparative antidepressant selection in major depressive disorder: systematic review
10.2196/89352 · 2026 · External reference
Multi-omics approach identifies gut microbiota variations associated with depression
10.1038/s41522-025-00707-9 · 2025 · External reference
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update
10.1002/cpt.597 · 2017 · External reference
Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017
10.1055/s-0043-116492 · 2018 · External reference
Dose-dependent inhibition of CYP2D6 by bupropion in patients with depression
10.1097/jcp.0000000000001387 · 2021 · External reference
The metabolome-wide signature of major depressive disorder
10.1038/s41380-024-02613-6 · 2024 · External reference
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial
10.1016/j.psyneuen.2017.01.023 · 2017 · External reference
The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder
10.1038/s41398-024-03208-z · 2024 · External reference
Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication
10.1038/s41398-021-01632-z · 2021 · External reference
Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants
10.1038/s41398-019-0589-0 · 2019 · External reference
Peripheral blood transcriptomic biomarkers for predicting antidepressant response in major depressive disorder
10.1186/s12888-026-07893-6 · 2026 · External reference
Phenoconversion of cytochrome P450 metabolism: a systematic review
10.3390/jcm9092890 · 2020 · External reference
Identifying predictive proteomic biomarkers of selective serotonin reuptake inhibitor treatment effect in depression
10.1080/17520363.2026.2641467 · 2026 · External reference
Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis
10.1038/s41380-019-0474-5 · 2020 · External reference
Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression
10.1038/s41398-020-01097-6 · 2021 · External reference
The identification, assessment and management of difficult-to-treat depression: a review of current literature and a consensus statement
10.1016/j.jad.2020.02.023 · 2020 · External reference
Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial
10.1038/s41386-020-00948-6 · 2021 · External reference
Predicted plasma proteomics from genetic scores and treatment outcomes in major depression: a meta-analysis
10.1016/j.euroneuro.2025.05.004 · 2025 · External reference
Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME Care randomized clinical trial
10.1001/jama.2022.9805 · 2022 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · 2021 · External reference
Therapeutic drug monitoring of antidepressants: an underused but potentially valuable tool in primary care
10.3389/fpsyt.2022.867840 · 2022 · External reference
A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers
10.1001/2013 · 2013 · External reference
PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews
10.1186/s13643-020-01542-z · 2021 · External reference
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report
10.1176/ajp.2006.163.11.1905 · 2006 · External reference
Epigenome-wide DNA methylation in unipolar depression: predictive biomarker of antidepressant treatment response?
10.1093/ijnp/pyae045 · 2024 · External reference
Transcriptomic profiles in major depressive disorder: the role of immunometabolic and cell-cycle-related pathways in depression with different levels of inflammation
10.1038/s41380-024-02736-w · 2025 · External reference
Pharmacogenomic scores in psychiatry: systematic review of current evidence
10.1038/s41398-024-02998-6 · 2024 · External reference
RoB 2: a revised tool to assess risk of bias in randomized trials
10.1136/bmj.l4898 · 2019 · External reference
Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis
10.3389/fpsyt.2024.1276410 · 2024 · External reference
An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline
10.1176/appi.ajp.2014.14010094 · 2014 · External reference
PROBAST: a tool to assess the risk of bias and applicability of prediction model studies
10.7326/m18-1376 · 2019 · External reference
Baseline gut microbiota profiles affect treatment response in patients with depression
10.3389/fmicb.2024.1429116 · 2024 · External reference
Evaluating the impact of machine learning models on adult major depressive disorder using conventional treatment strategies: a systematic review approach
10.1186/s12982-025-00816-y · 2025 · External reference
